Overall incidence of evaluated clinical outcomes (n = 390)
| Clinical outcome . | % (95% CI) . |
|---|---|
| 100 days (acute) | |
| Grade III-IV GVHD | 21 (17-25) |
| 100-day GI GVHD | |
| Grade II-IV | 14 (11-18) |
| Grade III-IV | 8 (5-11) |
| 1-year chronic GVHD | 53 (48-58) |
| Rate of relapse | |
| 100 d | 2 (1-4) |
| 6 mo | 5 (3-8) |
| 1 y | 10 (7-13) |
| Overall survival | |
| 100 d | 85 (82-89) |
| 6 mo | 77 (73-81) |
| 1 y | 67 (62-72) |
| Disease-free survival | |
| 100 d | 84 (80-88) |
| 6 mo | 74 (70-78)) |
| 1 y | 63 (58-68) |
| Clinical outcome . | % (95% CI) . |
|---|---|
| 100 days (acute) | |
| Grade III-IV GVHD | 21 (17-25) |
| 100-day GI GVHD | |
| Grade II-IV | 14 (11-18) |
| Grade III-IV | 8 (5-11) |
| 1-year chronic GVHD | 53 (48-58) |
| Rate of relapse | |
| 100 d | 2 (1-4) |
| 6 mo | 5 (3-8) |
| 1 y | 10 (7-13) |
| Overall survival | |
| 100 d | 85 (82-89) |
| 6 mo | 77 (73-81) |
| 1 y | 67 (62-72) |
| Disease-free survival | |
| 100 d | 84 (80-88) |
| 6 mo | 74 (70-78)) |
| 1 y | 63 (58-68) |
CI indicates confidence interval; GI, gastrointestinal; and GVHD, graft-versus-host disease.